- The Federal Reserve on Tuesday voiced concern about stretched valuations in certain corners of the U.S. equity markets, including the small cap, biotechnology and social media sectors.
The unusual comments from the Fed's monetary policy report - the first time in 14 years that the Fed has commented specifically on valuation of a particular equity sector - that accompanied Fed Chair Janet Yellen's semi-annual testimony to Congress, hit stocks in riskier sectors of the market.
Yellen said in remarks to the Senate Banking Committee that valuations across equity markets remain generally in line with long-term averages, but the Fed's report said the forward price-to-earnings multiples for smaller companies and those in the biotechnology and social media sectors appear "high relative to historical norms."
No need to speak about Bio stocks until you talk to me.
Old being spanked by Jan
Sr Hola. the Germans are a machine butt your home team put up a great effort.
110degrees F here today. Not playing for a few days. I found an old poster from WFR days.
CaptionPussy and a few people have a board about like ours. I
didn't say much there, I'm using them for some ideas. AGCYF I believe is the symbol,
Old just win baby
Wow the best song in the history of r&b-no really
I think that is what those people are drinking over at USU-a bankrupt company that received a small contract from the Government for 2.5 million. This stock went from about 3 to a little over 12 in short time. Can you short a bk stock? Maybe time to put the others on a close watch.
STEM taking off on a upgrade, put in a limit order at about 2.15 and don't think I'll get filled, maybe next week.
Old dancing with Pointer Sisters.
I bough a basket of bio for the retirement account. I will add BLUE KITE and SRPT in the near future.
Today 300 IMGN 200 ISIS 500CUR 300 CLDX 500 QURE. I should have bought ZU when the Grandbaby told mee about it. She'll be a seven year old fashionista next week.
I'm sticking with mee basket for at least a year one of them will buy that convertible the wife has her eye on.
I almost started a mobile mammography business back in the 80's. Well I sold what KITE I had and picked up a 1x of XCO for an earnings play. She reports tomorrow after close.
Well I was late getting into KITE but even at least for day1. I did well with ISIS and CUR today also. BLUE that I sold hit almost 41 today. I added some SGMO and pulled weOlded in the back yard, Ha.
Good weekend all
The CART field has become one of the hottest in drug development because the cells, though cumbersome and currently made individually for every patient, have shown amazing results in a small number of patients, making blood cancers seem to disappear and then stay vanished. (See: Is This How We’ll Cure Cancer?) Novartis has made a big bet on the cells. It’s main competition is Juno Therapeutics, one of the hottest startups in biotech with more than $176 million in its first round of investment, but others have lined up behind, including Kite Pharma and the team of gene therapy developer Bluebird Bio and biotech giant Celgene.
Cellectis’ cells are way behind all of those competitors; Novartis is pushing forward with a trial to test its cells against acute lymphoblastic leukemia and chronic lymphocytic leukemia in a large number of patients, and Juno has programs that might be only a little behind. Pfizer’s release says that the two companies will work together on preclinical research, meaning that they have not even entered human trials.
I put in a limit order early and didn't get filled. I was distracted with other things and had to leave now will wait a bit and buy any dip if there is one..
I have to agree this could be one a handful that will change everything . I have some BLUE and SGMO that are somewhat similar.
Good luck tomorrow.